Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, June 19, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced pre-clinical data on the combination of TG-1101 plus TGR-1202 was presented in the Novel Monoclonal Antibodies Oral Session during the 12th International Conference on Malignant Lymphoma which was held in Lugano, Switzerland.
Help employers find you! Check out all the jobs and post your resume.
NEW YORK, June 19, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced pre-clinical data on the combination of TG-1101 plus TGR-1202 was presented in the Novel Monoclonal Antibodies Oral Session during the 12th International Conference on Malignant Lymphoma which was held in Lugano, Switzerland.
Help employers find you! Check out all the jobs and post your resume.
